血清可溶性 ST2 作为一种新型生物标志物，反映 COVID-19 患者的炎症状态和疾病严重程度。
Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19.
机构信息
Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Hubei, Wuhan, 430071, China.
National Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai, 200433, China.
出版信息
Biomark Med. 2020 Dec;14(17):1619-1629. doi: 10.2217/bmm-2020-0410.
The authors studied the role of soluble ST2 (sST2) in COVID-19 and its relationship with inflammatory status and disease severity. Serum levels of sST2 and interleukin (IL)-33, C-reactive protein (CRP), serum amyloid protein (SAA), IL-6 and procalcitonin (PCT), and T lymphocyte subsets from 80 subjects diagnosed with COVID-19 including 36 mild, 41 severe and three asymptomatic cases were tested. Serum sST2 levels were significantly increased in COVID-19 patients, which were positively correlated with CRP, but negatively correlated with CD4 and CD8 T lymphocyte counts. Serum sST2 levels in nonsurviving severe cases were persistently high during disease progression. Serum sST2 level test is helpful for reflecting inflammatory status and illness severity of COVID-19.
研究人员研究了可溶性 ST2（sST2）在 COVID-19 中的作用及其与炎症状态和疾病严重程度的关系。检测了 80 例 COVID-19 患者（包括 36 例轻症、41 例重症和 3 例无症状）的血清 sST2 和白细胞介素（IL）-33、C 反应蛋白（CRP）、血清淀粉样蛋白（SAA）、IL-6 和降钙素原（PCT）水平，以及 T 淋巴细胞亚群。COVID-19 患者血清 sST2 水平显著升高，与 CRP 呈正相关，与 CD4 和 CD8 T 淋巴细胞计数呈负相关。在疾病进展过程中，重症非存活病例的血清 sST2 水平持续升高。血清 sST2 水平检测有助于反映 COVID-19 的炎症状态和疾病严重程度。
Zotero 插件